ARS Pharmaceuticals (SPRY) Profit After Tax Growth (1y) (2021 - 2026)
ARS Pharmaceuticals (SPRY) Profit After Tax Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 0.26% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -107.76% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 101.22% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | ARS Pharmaceuticals | 576.91 Mn | 375.94 Mn | - | -78.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.60% |
| Dec 31, 2025 | -182.66% |
| Sep 30, 2025 | -174.15% |
| Jun 30, 2025 | -258.95% |
| Mar 31, 2025 | -224.32% |
| Dec 31, 2024 | 799.01% |
| Sep 30, 2024 | -25.41% |
| Jun 30, 2024 | 28.84% |
| Mar 31, 2024 | 31.60% |
| Dec 31, 2023 | 50.32% |
| Sep 30, 2023 | -125.82% |
| Jun 30, 2023 | -174.42% |
| Mar 31, 2023 | -111.03% |
| Dec 31, 2022 | -131.50% |
| Sep 30, 2022 | 70.99% |
| Jun 30, 2022 | 73.79% |
| Mar 31, 2022 | 61.57% |
| Dec 31, 2021 | 450.09% |
| Sep 30, 2021 | -179.56% |
| Jun 30, 2021 | -278.78% |